NCT02919111View on ClinicalTrials.gov

Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

299

Participants

Timeline

Start Date

September 23, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Ga-68 labeled PSMA-11 PET

Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.

Trial Locations (1)

94107

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT02919111 - Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients | Biotech Hunter | Biotech Hunter